255 related articles for article (PubMed ID: 37725623)
1. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
[TBL] [Abstract][Full Text] [Related]
2. Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment.
Takahashi M; Saito K; Ai T; Nojiri S; Khasawneh A; Paran FJ; Horiuchi Y; Takei S; Yamamoto T; Wakita M; Hiki M; Miida T; Naito T; Takahashi K; Tabe Y
PLoS One; 2023; 18(1):e0279779. PubMed ID: 36693058
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL
J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095
[TBL] [Abstract][Full Text] [Related]
4. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
6. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
8. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
10. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
11. Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies.
Takahashi M; Ai T; Sinozuka K; Baba Y; Igawa G; Nojiri S; Yamamoto T; Yuri M; Takei S; Saito K; Horiuchi Y; Kanno T; Tobiume M; Khasawneh A; Paran FJ; Hiki M; Wakita M; Miida T; Suzuki T; Okuzawa A; Takahashi K; Naito T; Tabe Y
Sci Rep; 2022 Sep; 12(1):14909. PubMed ID: 36050347
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
13. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
14. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
15. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2.
Malipiero G; D'Agaro P; Segat L; Moratto A; Villalta D
Clin Chim Acta; 2022 Jan; 524():11-17. PubMed ID: 34843705
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
17. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
19. RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers.
Aguilar R; Li X; Crowell CS; Burrell T; Vidal M; Rubio R; Jiménez A; Hernández-Luis P; Hofmann D; Mijočević H; Jeske S; Christa C; D'Ippolito E; Lingor P; Knolle PA; Roggendorf H; Priller A; Yazici S; Carolis C; Mayor A; Schreiner P; Poppert H; Beyer H; Schambeck SE; Izquierdo L; Tortajada M; Angulo A; Soutschek E; Engel P; Garcia-Basteiro A; Busch DH; Moncunill G; Protzer U; Dobaño C; Gerhard M
Microbiol Spectr; 2023 Feb; 11(1):e0316522. PubMed ID: 36622140
[TBL] [Abstract][Full Text] [Related]
20. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
Luo YR; Yun C; Chakraborty I; Wu AHB; Lynch KL
J Clin Microbiol; 2021 Jun; 59(7):e0019321. PubMed ID: 33827900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
